Brinker, CytRx, Cummins, KBR, Lexmark, SanDisk: U.S. Equity Movers Final

(Bloomberg) -- The following is a list of companies
whose shares had unusual price changes in U.S. exchanges today.
Stock symbols are in parentheses after company names. Share
prices are as of 4 p.m. New York time.

Alnylam Pharmaceuticals Inc. (ALNY US) rose $7.92, or 52
percent, to $23.12. Roche Holding AG (ROG VX), the world's
biggest maker of cancer medicines, may pay as much as $1 billion
for rights to Alnylam technology that may allow the companies to
find new tumor, liver and breathing treatments.


Read more at Bloomberg Stocks News

U.S. Stock-Index Futures Gain; Alcoa, Boeing, Alnylam Advance in Europe

(Bloomberg) -- U.S. stock-index futures rose on
speculation companies' earnings will beat analyst estimates.

Alcoa Inc., the world's second-largest aluminum company,
gained in Europe before reporting second-quarter income. Boeing
Co. climbed after unveiling its 787 Dreamliner. Alnylam
Pharmaceuticals Inc. soared as Roche Holding AG, the world's
biggest maker of cancer medicines, agreed to buy the rights to
the company's therapeutic technology for up to $1 billion.


Read more at Bloomberg Stocks News

Roche signs up to $1 bln deal with Alnylam on RNAi

(Reuters) - LONDON/ZURICH, July 9 - Roche Holding AG has signed a deal worth up to $1 billion with Alnylam Pharmaceuticals Inc. , giving it access to the U.S. firm's skills in the new science of RNA interference.



The agreement is the largest drug discovery partnership in the field to date and a further vindication of the emerging area of biotechnology research, which involves blocking disease-causing proteins.


Read more at Reuters.com Mergers News

Anadarko, Atlas, Cholestech, Scholastic, UAL Corp.: U.S. Equity Movers

(Bloomberg) -- The following is a list of companies
whose shares are having unusual price changes in U.S. exchanges
today. Stock symbols are in parentheses after company names.
Share prices are as of 1:10 p.m. New York time.

Amylin Pharmaceuticals Inc. (AMLN US) fell $1.76, or 3.8
percent, to $45 and traded as high as $45.69. The pharmaceutical
company said in a statement send by PR Newswire that it intends
to sell $400 million of convertible bonds to help fund drug
development and market products that are approved for sale.


Read more at Bloomberg Stocks News